- Conditions
- Healthy
- Interventions
- LY3462817 (SC), Placebo (SC), LY3462817 (IV), Placebo (IV)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 3,862
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Ovarian Cancer, Triple Negative Breast Cancer
- Interventions
- Atezolizumab, RO6870810
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
- Conditions
- Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic, Diseases Inborn, Skin, Disease, Eczematous Skin, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases, Dermatitis, Atopic
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 31 more
- Conditions
- Chronic Pruritus of Unknown Origin
- Interventions
- nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fountain Valley, California + 22 more
- Conditions
- Hematological Malignancies
- Interventions
- Teclistamab (IV), Teclistamab(SC)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 5
- States / cities
- Duarte, California • Denver, Colorado • New York, New York + 2 more
- Conditions
- Cutaneous T-Cell Lymphoma
- Interventions
- HuMax-CD4
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 2
- States / cities
- Stanford, California • Houston, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Efsitora Alfa, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Concord, California • Escondido, California + 34 more
- Conditions
- Multiple Sclerosis
- Interventions
- peginterferon beta-1a, Rebif
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Pancreatic Cancer, Adenocarcinoma of the Pancreas, Adenocarcinoma
- Interventions
- Motixafortide, Cemiplimab, Gemcitabine, Nab paclitaxel
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • New York, New York • Providence, Rhode Island + 1 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2944876, Exenatide extended-release, Placebo, Metformin
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 31
- States / cities
- Concord, California • Fresno, California • Los Angeles, California + 27 more
- Conditions
- Transplantation, Stem Cell
- Interventions
- Ronacaleret 100 mg, Ronacaleret 400 mg, Plerixafor
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Overweight, Obesity
- Interventions
- LY3537031, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 22 Years to 65 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Los Alamitos, California • Daytona Beach, Florida • Miami, Florida + 2 more
- Conditions
- Other Skin
- Interventions
- Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Avelumab, Pembrolizumab, Interferon Gamma-1b
- Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Crohn Disease
- Interventions
- Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
- Drug · Procedure · Biological
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 13 Years to 28 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 51
- States / cities
- Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
- Conditions
- Healthy Volunteer
- Interventions
- Lebrikizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 4
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more
- Conditions
- Colorectal Cancer
- Interventions
- IMO-2055, Cetuximab, FOLFIRI
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
- Conditions
- Dermatitis, Atopic
- Interventions
- MK-6194, Placebo
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- North Little Rock, Arkansas • Miami, Florida • Miami Lakes, Florida + 9 more
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boca Raton, Florida
- Conditions
- Osteoporosis, Arthroplasties, Knee Replacement
- Interventions
- Abaloparatide
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Rheumatoid Arthritis
- Interventions
- Sarilumab, Adalimumab, Placebo (for sarilumab), Placebo (for adalimumab)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 17
- States / cities
- Covina, California • Long Beach, California • Whittier, California + 14 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- LY3471851, Placebo
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • La Jolla, California • Clearwater, Florida + 11 more
- Conditions
- Psoriasis
- Interventions
- Drug Cocktail, Ixekizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Anaheim, California • DeLand, Florida • High Point, North Carolina
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 44
- States / cities
- Mobile, Alabama • Concord, California • Escondido, California + 40 more